ThermoGenesis Announces Sale of Thermoline Product Line to Helmer Scientific

ThermoGenesis Announces Sale of Thermoline Product Line to Helmer Scientific

RANCHO CORDOVA, Calif., Jan. 3, 2013 (GLOBE NEWSWIRE) -- ThermoGenesis Corp.
(Nasdaq:KOOL), a leading supplier of enabling technologies for the processing,
storage and administration of cell therapies, today said it has sold its
ThermoLine plasma freezer and thawer product line to Helmer Scientific for an
undisclosed sum of cash. ThermoGenesis received the payment during the quarter
ended December 31, 2012.

"As was the case with our divestiture of the CryoSeal product line in
mid-2012, this transaction is part of our long-term strategy to focus on our
core business of developing enabling technologies for the stem cell
regenerative medicine market," said Matthew Plavan, Chief Executive Officer of

"The proceeds from this transaction will be used to fund market development
programs for our cord blood and bone marrow stem cell processing and storage
offerings. In addition, this divestiture will reduce some operating costs and
free up internal resources that were previously used to provide customer
support and service for ThermoLine customers," he added.

Helmer Scientific is a world leader in providing specialized scientific
products that aid customers in their efforts to improve and save lives. Based
in Noblesville, IN, Helmer provides solutions for storage and processing in
the blood bank and laboratory. The acquisition is part of Helmer's growth
strategy and a continuing commitment to providing high quality products to the
medical and blood bank community.

Bruce King, President of Helmer Scientific said of the acquisition; "This line
acquisition is focused on providing a solution to our customers who have
voiced a need for a reliable rapid plasma freezing system. Helmer Scientific's
long-standing service orientation and commitment to world-wide customer
relationships, combined with our technical expertise in blood storage and
processing equipment, uniquely position Helmer to support ThermoGenesis'
longtime customers with a service and support infrastructure for both their
freezing and thawing devices."

About ThermoGenesis Corp.

ThermoGenesis Corp. ( is a leader in developing and
manufacturing automated blood processing systems and disposable products that
enable the manufacture, preservation and delivery of cell and tissue therapy
products. These include:

  *The BioArchive^® System, an automated cryogenic device, used by cord blood
    stem cell banks in more than 30 countries for cryopreserving and archiving
    cord blood stem cell units for transplant.
  *AXP^® AutoXpress^® Platform (AXP), a proprietary family of automated
    devices that includes the AXP and the MXP^® MarrowXpress^® and companion
    sterile blood processing disposables for harvesting stem cells in closed
    systems. The AXP device is used for the processing of cord blood. The MXP
    is used for the preparation of cell concentrates, including stem cells
    from bone marrow aspirates in the laboratory setting.
  *The Res-Q^® 60 BMC/PRP (Res-Q), a point-of-care system designed for the
    preparation of cell concentrates, including stem cells, from bone marrow
    aspirates and whole blood for platelet rich plasma (PRP).

The ThermoGenesis Corp. logo is available at

About Helmer

Helmer Scientific is a world leader in providing specialized scientific
products that aid customers in their efforts to improve and save lives. Our
purpose is to provide opportunities for personal growth and development while
positively impacting the world community. Helmer provides solutions for
storage and processing while serving customers within hospitals, diagnostic
labs, pharmaceutical and biotech companies, universities, research
institutions, and government facilities. Our Brand Promise of targeted,
customer-focused innovation, world-class quality and reliability, and
relationship-based service sets us apart.

Helmer Global Initiatives (HGI) is operated by Helmer to make an impact on
society and bring aid and justice for poor and vulnerable people through our
philanthropic and volunteer initiatives.Additional information about Helmer
is available at

This press release contains forward-looking statements.These statements
involve risks and uncertainties that could cause actual outcomes to differ
materially from those contemplated by the forward-looking statements. Several
factors including timing of FDA and foreign regulatory approvals, changes in
customer forecasts, our failure to meet customers' purchase order and quality
requirements, supply shortages, production delays, changes in the markets for
customers' products, introduction timing and acceptance of our new products
scheduled for fiscal year 2013, and introduction of competitive products and
other factors beyond our control could result in a materially different
revenue outcome and/or in our failure to achieve the revenue levels we expect
for fiscal 2013.A more complete description of these and other risks that
could cause actual events to differ from the outcomes predicted by our
forward-looking statements is set forth under the caption "Risk Factors" in
our annual report on Form 10-K and other reports we file with the Securities
and Exchange Commission from time to time, and you should consider each of
those factors when evaluating the forward-looking statements.

CONTACT: ThermoGenesis Corp.
         Web site:
         Contact: Investor Relations
         +1-916-858-5107, or

ThermoGenesis Corp. Logo
Press spacebar to pause and continue. Press esc to stop.